Skip to main content
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • |
  • Alumni
  • The Peel
  • Athletics
Sections
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • |
  • Alumni
  • The Peel
  • Athletics
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit

SU professor presents new findings on chemotherapy drug, plans studies to further development of drugs with fewer side effects

Tuesday, March 28, 2006, By News Staff
Share

SU professor presents new findings on chemotherapy drug, plans studies to further development of drugs with fewer side effectsMarch 28, 2006Carol K. Masiclatclkim@syr.edu

For millions of people battling cancer, chemotherapy is a necessary fact of life. The powerful drugs used slow the abnormal, unregulated growth of cells (cancer) by attacking cells undergoing the division process. One such drug, cisplatin, has become one of the most widely used chemotherapy drugs in the world.

When it was approved by the Food and Drug Administration in 1978, platinum-based cisplatin revolutionized the treatment of various types of cancers, including testicular, ovarian, lung, esophagus (gullet), stomach and bladder cancers. Cisplatin, and another platinum drug, carboplatin, account for more than $2 billion in annual sales worldwide. But while the treatments with these drugs have been effective, they also often bring with them side effects that can range from mild to life threatening. One of cisplatin’s most common side effects is its high renal toxicity, which can lead to severe and permanent damage to the kidneys.

Recent discoveries by James Dabrowiak, Syracuse University professor of chemistry, and his collaborators at SU and at SUNY Upstate Medical University, may revolutionize how cancer is treated with cisplatin and related drugs. Using a highly sensitive form of nuclear magnetic resonance spectroscopy (NMR), Dabrowiak and his team discovered that platinum drugs react with carbonate present in the blood and cells. The result is the formation of adducts, called carbonato complexes, which may be the main chemical components responsible for cell death.

While carbonato complexes are very important for uptake, antitumor properties and toxicity, only small amounts of these compounds are naturally produced in the blood of patients receiving these drugs. For this reason, it is critical to make these compounds chemically and study their effects on normal and cancer cells.

“Our findings have turned over a number of existing concepts and beliefs on the molecular mechanism of action of cisplatin,” says Dabrowiak. “When the findings are fully appreciated and implemented, they will lead to the synthesis of new and more effective platinum drugs for treating cancer.”

Reducing the toxicity of cisplatin and carboplatin is an important priority in Dabrowiak’s work. The research may lead to modified versions of these drugs that enable patients to stay on treatments for longer periods of time without the risk of damage to important organs.

Says Dabrowiak: “That is a critical thing for the patient, reducing toxicity. It makes their lives easier and more comfortable, and their therapies are more effective.”

The research team has published two papers to share their findings, “Cisplatin Carbonato Complexes. Implications for Uptake, Antitumor Properties and Toxicity” in the October 2005 issue of the Journal of the American Chemical Society, and “Activation of Carboplatin by Carbonate” in the January 2006 issue of the ACS journal Chemical Research in Toxicology.

The next move for Dabrowiak and his collaborators is carrying out animal studies with platinum drugs that have been modified with carbonate. The team will continue to investigate the efficacy of carbonato complexes for treating tumors and minimizing drug-induced side effects.

  • Author

News Staff

  • Recent
  • Supporting, Advocating for Trans Youth Will Help Them Thrive As Adults
    Friday, May 26, 2023, By Daryl Lovell
  • 2023-24 Parking Rates Announced
    Friday, May 26, 2023, By News Staff
  • Lutheran Chaplain Announces Retirement
    Thursday, May 25, 2023, By Dara Harper
  • Dean J. Cole Smith Talks With FedEx President and CEO Raj Subramaniam G’89 About Leadership and Advice for Current Students
    Thursday, May 25, 2023, By Alex Dunbar
  • From Generation to Generation: Doing Well by Doing Good
    Thursday, May 25, 2023, By Eileen Korey

More In Uncategorized

Syracuse Views Spring 2023

We want to know how you experience Syracuse University. Take a photo and share it with us. We select photos from a variety of sources. Submit photos of your University experience using #SyracuseU on social media, fill out a submission…

Awards of Excellence Honoree: Maxwell has Been ‘a Guiding Hand’ in Public Service Career

Standing before an audience of fellow Maxwell School alumni gathered in Washington, D.C., for the second annual Maxwell Awards of Excellence, CNN anchor Boris Sanchez ’09 shared the motivation behind his work as a journalist. Sanchez emigrated from Cuba as…

NASA Honoring Those Who Were Aboard Space Shuttle Columbia And Other Late Astronauts

Sean O’Keefe, University Professor in the Maxwell School, was interviewed for the USA Today article “Twenty years later, loss of space shuttle Columbia still teaches us lessons.” The article emphasizes how NASA’s Memorial Grove is used to honor late astronauts,…

NFL, Eagles and Chiefs All Set To Win The Economics Game In Super Bowl LVII

Rodney Paul, director and professor of sport analytics in the Falk School, was quoted in the Washington Examiner story “The economics of the Super Bowl: Hosting, gambling, ads, and more.” The article talks in-depth about all of the economics that…

CEOs Requiring In Person Work Is Hurting Diversity

Arlene Kanter, director of the Disability and Policy Program and professor in the College of Law, was interviewed for the Business Insider article “Some CEOs are pushing workers to return to the office, but it could come with a cost:…

Subscribe to SU Today

If you need help with your subscription, contact sunews@syr.edu.

Connect With Us

  • Twitter
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
Social Media Directory

For the Media

Find an Expert Follow @SyracuseUNews
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • @SyracuseU
  • @SyracuseUNews
  • @SUCampus
  • Social Media Directory
  • Accessibility
  • Privacy
  • Campus Status
  • Syracuse.edu
© 2023 Syracuse University News. All Rights Reserved.